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Abstract: Combination therapies, where two drugs acting through different mechanisms are
administered simultaneously, are one of the most efficient approaches currently used to treat
malaria infections. However, the different pharmacokinetic profiles often exhibited by the combined
drugs tend to decrease treatment efficacy as the compounds are usually eliminated from the
circulation at different rates. To circumvent this obstacle, we have engineered an immunoliposomal
nanovector encapsulating hydrophilic and lipophilic compounds in its lumen and lipid bilayer,
respectively. The antimalarial domiphen bromide has been encapsulated in the liposome membrane
with good efficiency, although its high IC50 of ca. 1 µM for living parasites complicates its use as
immunoliposomal therapy due to erythrocyte agglutination. The conjugation of antibodies against
glycophorin A targeted the nanocarriers to Plasmodium-infected red blood cells and to gametocytes,
the sole malaria parasite stage responsible for the transmission from the human to the mosquito vector.
The antimalarials pyronaridine and atovaquone, which block the development of gametocytes, have
been co-encapsulated in glycophorin A-targeted immunoliposomes. The co-immunoliposomized
drugs have activities significantly higher than their free forms when tested in in vitro Plasmodium
falciparum cultures: Pyronaridine and atovaquone concentrations that, when encapsulated in
immunoliposomes, resulted in a 50% inhibition of parasite growth had no effect on the viability of the
pathogen when used as free drugs.
Keywords: combination therapy; immunoliposomes; malaria; nanomedicine; nanotechnology;
Plasmodium; targeted drug delivery
1. Introduction
Despite the undeniable importance of malaria elimination on the global research agenda, current
vaccines in development do not offer prospects of complete protection [1] and the available drugs are
rapidly losing efficacy, with resistance already evolved to the front-line drug artemisinin [2]. This
scenario has led to the continuing need of research for new antimalarial agents [3] and to the use of
combinations of drugs that do not share the same resistance mechanisms [4–6]. However, the different
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pharmacokinetic profiles often exhibited by the combined drugs tend to decrease treatment efficacy
as the compounds are usually eliminated from the circulation at different rates [7]. Encapsulation of
drugs in targeted nanovectors is a rapidly growing area with a clear applicability to infectious disease
treatment [8], and pharmaceutical nanotechnology has been identified as a potentially essential tool in
the future fight against malaria [9,10]. Liposomes (LPs) in particular are an ideal platform to develop
drug delivery systems for combination therapies at the nanoscale, due to their capacity to incorporate in
a single nanostructure molecules with widely diverging characteristics (and antimicrobial mechanisms),
namely, hydrophilic drugs in their aqueous core and lipophilic compounds in their lipid bilayer.
In all organisms studied so far, isopentenyl diphosphate (IPP) is a key intermediate of isoprenoid
biosynthesis [11]. In mammals and fungi, IPP is derived from the mevalonate pathway. In about
1993, the 2-C-methyl-d-erythritol-4-phosphate (MEP) pathway was identified as an alternative route
for the early steps in the biosynthesis of isoprenoids [12,13]. Whereas the MEP pathway is absent in
mammals, it is essential for many human pathogens, including Plasmodium [14], thus its enzymes are
attractive targets for the development of novel antimalarials. This metabolic route begins with the
condensation of glyceraldehyde-3-phosphate and pyruvate to yield 1-deoxy-d-xylulose 5-phosphate
(DOXP), which is subsequently converted to MEP by the enzyme DOXP reductoisomerase (DXR) [15].
The MEP pathway has been identified in the apicoplast, a relic chloroplast of Plasmodium and related
protists, where it plays an essential function for the pathogen’s survival [16,17], and, since it has
not been extensively used yet as a target to treat malaria, it is expected that the parasite will not
show significant resistance against inhibitors of its enzymes. The drug fosmidomycin inhibits the
recombinant DXR from Plasmodium falciparum with an IC50 value of ~28 nM and shows activity on the
intact parasite, both in in vitro P. falciparum cultures (IC50 between 290 and 370 nM depending on the
parasite strain) and in in vivo assays with mice infected with the rodent malaria species Plasmodium
vinckei [16]. In preliminary clinical trials fosmidomycin had been shown to be efficacious for the
treatment of malaria in children [18], although a high rate of relapse is complicating its use as a
monotherapy [19]. Presumably, compounds inhibiting other MEP pathway steps will also show
antiplasmodial activity. Fluoropyruvate, for instance, has been described as an inhibitor of bacterial
DOXP synthase [20], and is currently being studied as a potential new antimalarial [21]. The Malaria
Box compound MMV008138 targets the third enzyme of the MEP pathway, IspD, which catalyzes the
formation of 4-diphosphocytidyl-2-C-methyl-d-erythritol [22]. The quaternary ammonium compound
domiphen bromide (DB) has also been shown in in vitro enzyme activity assays to inhibit IspD from
Mycobacterium smegmatis [23] and from Plasmodium vivax [24].
Preexisting data indicate that the lipids used to assemble LPs targeted to Plasmodium-infected
red blood cells (pRBCs) were incorporated by the parasites [25]. The molecular dimensions of DB
suggest that it can be inserted into biological membranes to constitute a liposoluble drug cargo in a
LP designed for the targeted delivery of antimalarial combination therapies. As a potential partner
drug for such nanovessel, the water-soluble compound pyronaridine has shown high potency against
P. falciparum, including chloroquine-resistant strains [26]. Although several mechanisms of action have
been described for pyronaridine [26], its main target seems to be related to haem detoxification in
the food vacuole of the parasite. Resistance to pyronaridine appears to emerge slowly and is further
retarded when it is used in combination with other antimalarials, being its toxicity generally less
than that of chloroquine. The recent appreciation that efficient antimalarial strategies will require
the interruption of parasite transmission from the human host to the vector [27] has prompted the
search for transmission-blocking drugs [28]. One target of such drugs is the gametocyte, which is the
parasite stage solely responsible for Plasmodium transmission to the mosquito. Pyronaridine exhibits
a moderate inhibition of early gametocyte stages and is one of the few drugs active against mature
gametocyte transmission to Anopheles mosquitoes [29–31], which makes it an interesting compound for
combination therapies [29].
In addition to carrying the active ingredients, an optimal nanovector should be designed to have
specificity towards the cell type where therapeutic activity has to be unleashed. Using glycophorin
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A (GPA) as an immunoliposomal target present in both non-parasitized red blood cells (RBCs) and
in pRBCs, the efficacy of drugs encapsulated in LPs could be significantly improved due to the
prophylactic effect of loading antimalarial compounds into RBCs when these have not yet been
infected by Plasmodium [32–34]. Since GPA is also present in the gametocyte membrane, it is an
ideal receptor for targeting strategies against all blood stages of the malaria parasite. Here we have
integrated the strategies outlined above into the design of a GPA-targeted immunoliposome (iLP,
Figure 1) encapsulating in its aqueous lumen pyronaridine and in its lipid bilayer DB or the lipophilic
antimalarial drug atovaquone (whose site of action is complex III of the mitochondrial respiratory
chain [35]), with the objective of exploring the capacity of nanocarriers to be developed into new
antimalarial combination therapies at the nanoscale.
Figure 1. Scheme of the immunoliposome designed here for targeted antimalarial combination therapy.
2. Materials and Methods
2.1. Materials
Except where otherwise indicated, reagents were purchased from Sigma-Aldrich
Corporation (St. Louis, MO, USA), and reactions were performed at room
temperature (22 to 24 ◦C). The lipids (all ≥ 99% purity according to thin
layer chromatography analysis) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DSPE-PEG2000), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(DOPE-Rho) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene
glycol)-2000] (DSPE-PEG2000-Mal) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL,
USA) and stored at −20 ◦C. Monoclonal HIR2 antibodies raised against the N-terminal portion of GPA
were obtained from Acris Antibodies GmbH (Herford, Germany).
2.2. Generation of Liposomes
Liposomes were prepared by the thin lipid film hydration method [36] (Figure S1). The lipid
formulations DOPC/POPC/DSPC:DSPE-PEG2000:cholesterol 75:5:20 (DOPC-, POPC-, and DSPC-based
liposomes, respectively) were obtained by mixing stock solutions of lipids in chloroform:methanol (2:1
v/v) in a round bottom flask. When required for antibody binding, DSPE-PEG2000-Mal was substituted
for DSPE-PEG2000; when required for liposome labeling, 0.5% DOPE-Rho was incorporated in the
formulation, simultaneously reducing the DOPC, POPC, or DSPC content to 74.5%. Organic solvents
were removed by rotatory evaporation (RS 3000-V rotatory evaporator, Selecta) at 37 ◦C under reduced
pressure. The thin lipid film formed on the flask walls was hydrated in phosphate buffered saline (PBS,
pH 7.4) or in 200 mM citrate buffer, pH 3.5, in a volume corresponding to a final lipid concentration of
10 mM (unless otherwise specified all lipid concentrations refer to total lipid including cholesterol).
Mostly unilamellar LPs were obtained by 3 rounds of constant vortexing for 2 min followed by bath
Pharmaceutics 2019, 11, 341 4 of 19
sonication at 35 ◦C for 3 min (FB15053 ultrasonic bath, Thermo Fisher Scientific, Inc., Waltham, MA,
USA), and by extrusion through 400 nm polycarbonate membranes (Avanti Polar Lipids, Inc., Alabaster,
AL, USA) using a mini extruder device (Avanti Polar Lipids, Inc., Alabaster, AL, USA). Throughout the
lipid film hydration and downsizing processes, samples were maintained above the lipids’ transition
temperature. Sterility of LP samples was maintained by rinsing all material in 70% ethanol and
working in a laminar flow hood. After each preparation all materials were immersed in 70% ethanol,
sonicated for 15 min at 60 ◦C, and, finally, thoroughly rinsed with double-distilled water (ddH2O,
MilliQ system, Millipore, Burlington, MA, USA). Dynamic light scattering size and polydispersity
measurement of LPs was done after 1:30 sample dilution in PBS, using a Zetasizer NanoZS90 (Malvern
Ltd., Malvern, UK).
2.3. Encapsulation of Drugs in Liposomes
DOPC-based LPs containing DB in their membrane were generated by the thin lipid film hydration
method, adding the desired amount of a 50 mM DB stock solution in methanol to the initial lipid
composition dissolved in chloroform:methanol (2:1 v/v) to form LPs with molar ratios lipid:DB of 10:1,
10:2.5, and 10:5. In preliminary assays, liposome preparations containing DB in their lipid bilayers were
examined using different lipids as the main formulation component. Whereas DSPC (saturated)-based
liposomes resulted in large aggregates (Figure S2A), DOPC (unsaturated)-based liposome suspensions
consisted of vesicles with a mean diameter around 180 nm (Figure S2B,C) and a polydispersity index
of 0.36.
POPC-based LPs containing atovaquone in their membrane were also generated by the thin lipid
film hydration method, adding the desired amount of a 1 mM atovaquone stock solution in methanol
to the initial lipid composition dissolved in chloroform:methanol (2:1 v/v) to form LPs with molar ratios
lipid:atovaquone of 10:0.125, 10:0.5, and 10:1. In preliminary assays, liposome preparations containing
atovaquone in their lipid bilayers were examined using different lipids as the main formulation
component. Whereas DOPC-based liposomes resulted in a poorer atovaquone encapsulation, as after
24 h a yellow precipitate (free atovaquone) was observed, POPC-based LPs offered a more stable
preparation, without any observable precipitate (data not shown).
For pyronaridine encapsulation, unilamellar LPs were formed in 200 mM citrate buffer, pH 3.5,
which was exchanged with PBS at pH 7.4 using 7-kDa ZebaTM spin desalting columns (Thermo Fisher
Scientific, Inc.), creating a pH gradient between the outside and the inside of the LPs (Figure S1). In
order to avoid osmotic rupture of the LPs during buffer exchange, PBS was made isotonic with the
citrate buffer by addition of NaCl while measuring osmolarity with an Advanced InstrumentsTM
Micro-Sample Model 3320 Osmometer (Thermo Fisher Scientific, Inc.). To these pH gradient-holding
LPs (containing 10 mM lipid) was added one volume of 2× concentrated pyronaridine solution in PBS,
and this mixture was kept at room temperature for 17 h before drug encapsulation was quantified (see
below). Non-encapsulated pyronaridine was removed by pelleting liposomes by ultracentrifugation
(150,000× g, 2.5 h, 4 ◦C) and substituting the supernatant by isotonic PBS. Drug-encapsulating LPs
were stored at 4 ◦C for up to 14 days.
2.4. Generation of Immunoliposomes
Immunoliposomes were obtained by coupling anti-GPA antibody to the maleimide group
in DSPE-PEG2000-Mal following established protocols [32] (Figure S3), which resulted in the
incorporation, on average, of ca. 85 antibody molecules/liposome. Briefly, anti-GPA stock solutions
(1 mg/mL) were buffer exchanged with PBS and incubated at room temperature for 30 min with
N-succinimidyl-S-acetylthioacetate crosslinker (SATA, Thermo Fisher Scientific, Inc.) at a molar
ratio of anti-GPA:SATA 1:10; unreacted SATA was removed by buffer exchange with PBS. Thioester
groups on the anti-GPA-bound SATA were deacetylated through addition at room temperature
of 0.1 volume of 500 mM hydroxylamine, 25 mM EDTA in PBS. After deacetylation, thiolated
anti-GPA was buffer exchanged with osmolarity-adjusted PBS buffer supplemented with 10 mM
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EDTA. Maleimide-containing LPs were coupled to thiolated anti-GPA by incubation for 17 h at room
temperature. For pyronaridine-encapsulating iLPs, pyronaridine solution was added 30 min before
the anti-GPA solution and the mixture was also incubated for 17 h at room temperature. Free anti-GPA
and pyronaridine were finally removed by ultracentrifugation (150,000× g, 2.5 h, 4 ◦C).
2.5. Quantification of Encapsulated Drugs
Liposomes encapsulating (i) pyronaridine, (ii) DB, or (iii) atovaquone were disrupted by treatment
with, respectively, (i) one volume of 4% SDS, (ii) 3 volumes of DMSO, or (iii) 3 volumes of lysis
buffer (2.66% SDS, 0.166 mM NaOH and 33% DMSO in H2O). Drugs present in the resulting
solutions were quantitated by absorbance spectroscopy (EpochTM microplate spectrophotometer,
BioTek Instruments, Inc., Winooski, VT, USA), measuring A426nm for pyronaridine, A270nm for DB,
and A278nm for atovaquone; the corresponding absorbances of drug-free liposomes were subtracted.
Encapsulation efficiencies are defined as the fraction of encapsulated drug relative to the initially
added concentration.
2.6. P. falciparum Cultures
The 3D7 P. falciparum strain was cultivated in blood group B human RBCs (3% hematocrit)
following standard protocols [37]. The human blood used in this work was commercially obtained
from the Banc de Sang i Teixits (www.bancsang.net). Blood was not specifically collected for this
research; the purchased units had been discarded for transfusion, usually because of an excess of blood
relative to anticoagulant solution. Prior to their use, blood units underwent the analytical checks
specified in the current legislation. Before being delivered to us, unit data were anonymized and
irreversibly dissociated, and any identification tag or label had been removed in order to guarantee the
non-identification of the blood donor. No blood data were or will be supplied, in accordance with
the current Spanish Ley Orgánica de Protección de Datos and Ley de Investigación Biomédica. The blood
samples will not be used for studies other than those made explicit in this research. The studies
reported here were performed under protocols reviewed and approved by the Ethical Committee on
Clinical Research from the Hospital Clínic de Barcelona (Reg. HCB/2014/0910, October 14, 2014).
Parasites (thawed from glycerol stocks) were grown at 37 ◦C in Roswell Park Memorial Institute
complete medium containing AlbuMAX® II (RPMI-A, Gibco, Glasgow, UK) under a gas mixture of
92% N2, 5% CO2, and 3% O2. P. falciparum-infected erythrocytes were identified by staining their nuclei
for 10 min with Giemsa (Merck Chemicals, Darmstadt, Germany) diluted 1:10 in Sorenson’s buffer,
pH 7.2, and microscopically counted in blood smears fixed with methanol. For culture maintenance,
parasitemia was kept below 5% late forms and 10% early forms by dilution with freshly washed RBCs
and RPMI-A was changed every 1–2 days. Cultures were synchronized in early ring stages (0–24 h
post-invasion) by 5% sorbitol lysis [38]. Gametocytes were obtained using the gametocyte-generating
E5 subclone of the 3D7 strain, kindly provided by Dr. Alfred Cortés. Briefly, a culture containing 10%
rings was supplemented with 50 mM N-acetylglucosamine to inhibit asexual replication and select
those sexually committed ring stage parasites. After 24 h the medium was replaced daily for 2 weeks
with RPMI-A containing 50 mM N-acetylglucosamine, without further adding fresh blood.
2.7. Growth Inhibition Assays of P. falciparum Blood Stages
In vitro growth inhibition assays were conducted using synchronized P. falciparum cultures (>95%)
in the early ring stage at 4% hematocrit and 1.5% parasitemia as previously described [32]. Unless
otherwise specified, one culture volume of 2× concentrated drug solution in RPMI-A was added to
the parasitized cell suspension, and cultures were incubated under orbital stirring in Petri dishes.
After 15 min, cultures were transferred to microcentrifuge tubes and washed 3× (5 min, 300× g) with
fresh RPMI-A, incubating for 15 min between washes. Prior to each wash and after the last wash,
triplicates of small volume fractions of cultures were seeded in a 96-well plate and further incubated
for a complete 48 h growth cycle under the conditions described above. For the determination of
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parasitemia, samples were diluted 1:100 in isotonic PBS and the nuclei of pRBCs (the only nucleated
cells present in the culture) were stained by addition of 0.1 µM Syto11 (Thermo Fisher Scientific, Inc.)
in the final mixture before proceeding to flow cytometry analysis (see below). Growth inhibition
in drug-treated samples was defined as the percentage decrease in parasitemia within the second
generation of parasites relative to untreated control samples. Growth inhibition graphs and IC50
values were obtained through sigmoidal fitting of growth data at different drug concentrations using
the GraphPad Prism Software version 6.00 (www.graphpad.com; San Diego, CA, USA). For IC50
calculation, a Sigmoidal 4PL curve fitting model was used (fixed top = 100, fixed bottom = 0, confidence
interval = 95%), where X was the logarithm of drug concentration and Y was the percentage of growth
inhibition relative to untreated control samples.
2.8. Cell Binding Assays
Different solutions of decreasing iLP and LP concentrations were obtained through serial dilution
in RPMI-A, mixed with one sample volume of a RBC or pRBC culture prepared at 6% hematocrit (and
3% parasitemia in the case of pRBC assays), and incubated (15 min, 23 ◦C, 700 rpm) in a Thermomixer
comfort (Eppendorf AG, Hamburg, Germany). Prior to analysis, samples were diluted 1:100 in PBS
and centrifuged for 5 min at 300× g, except for flow cytometry analysis (see below), where cells were
pelleted at 100× g. Stock solutions not undergoing centrifugation and supernatants were analyzed by
fluorescence spectroscopy measurement of DOPE-Rho incorporated in the LP formulations (SynergyTM
HT multidetection microplate reader, BioTek Instruments, Inc.) with a 530/25 nm excitation filter and a
645/40 nm emission filter. Fluorescence readings were carried out in duplicates.
2.9. Liposome Stability and Drug Release Assays
For stability assays, LPs containing pyronaridine were stored at 4 ◦C and at different timepoints
encapsulated pyronaridine was determined by absorption spectroscopy, as described above. For drug
release assays LPs containing pyronaridine were ultracentrifuged (150,000× g, 2.5 h, 4 ◦C) and pellets
were resuspended in RPMI-A, pRBC or RBC cultures, or osmolarity-adjusted PBS to obtain a liposome
suspension containing 5 mM lipid. In order to simulate the conditions in P. falciparum cultures,
LPs resuspended in RPMI-A were mixed in a Thermomixer comfort (15 min, 23 ◦C, 700 rpm) and
subsequently warmed in a PSC96 Thermoblock (Grant Instruments Ltd., Cambridge, UK) at 37 ◦C.
At different timepoints liposomes were pulled down (150,000× g, 45 min, 4 ◦C) and pyronaridine
concentration in the supernatants was determined by absorption spectroscopy as described above.
Two additional control samples were included: Sonicated LPs containing pyronaridine (65 ◦C, 20 min
sonication) and LPs containing pyronaridine treated with one sample volume of 4% SDS. Drug
release was defined as the percentage of pyronaridine found in the supernatant relative to the initially
encapsulated drug.
2.10. Flow Cytometry
For targeting and growth inhibition assays, samples were analyzed at 0.02% hematocrit in PBS with
a BD LSRFortessaTM cell sorter (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Forward-
and side-scatter areas in a linear scale were used to gate the RBC population. Syto11-stained pRBCs were
detected by excitation through a 488 nm laser at 50 mW power and emission collection with a 530/30
nm bandpass filter in logarithmic scale. RBCs targeted by DOPE-Rho-containing anti-GPA iLPs were
detected by excitation through a yellow–green 561 nm laser at 50 mW power and emission collection with
a 610/20 nm bandpass filter and a 600 nm long pass dichroic mirror (PE-TRED-YG-channel) in logarithmic
scale. Acquisition was configured to stop after recording ≥ 10,000 events in the RBC population. In order
to accurately determine the parasitemia of cultures by flow cytometry, only singlets were used. RBC
agglutinates were removed from the analysis by discarding cytometer events with a disproportion on the
forward-scattered light height-area (H-A) confronted parameters, which indicated the presence of cell
doublets and agglutinates as previously described [32].
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2.11. Fluorescence Microscopy
For microscopy targeting analysis, pRBCs present in the samples were stained by incubation with
0.2 µg/mL Hoechst 33342 (Molecular Probes) and placed into a Nunc™ Lab-Tek™ chambered coverglass
prior to image acquisition with an Olympus IX51 inverted system microscope, equipped with an
IX2-SFR X-Y stage, a U-TVIX 2 camera, and a fluorescence mirror unit cassette for UV/blue/green
excitation and detection of their respective blue/green/red emission ranges.
2.12. Cryogenic Transmission Electron Microscopy (cryoTEM)
After glow-discharge to make the carbon film on a Holey Carbon 400-mesh copper grid hydrophilic,
a 3-µL drop of the sample was deposited onto it. The grid was mounted on an EM GP plunger
(Leica Microsystems GmbH, Wetzlar, Germany) and blotted with a Whatman No. 1 filter paper. The
LP dispersion was immediately vitrified by rapid immersion in liquid ethane. The grid with the
vitrified sample was mounted on a Gatan 626 cryo-transfer system and inserted into a Jeol JEM 2011
cryo-electron microscope operated at 200 kV, under low-dose conditions, and using different degrees
of defocus (500–900 nm) to obtain an adequate phase contrast. Images were recorded on a Gatan
Ultrascan US1000 CCD camera and analyzed with the Digital Micrograph 1.8 software.
3. Results
3.1. Liposome Encapsulation of Pyronaridine
Depending on the pH, pyronaridine (Figure 2A) can be present in different ionization forms
according to the pKas of its hydroxyl group and three protonable amino groups [39]. At the blood pH
of 7.4 pyronaridine is relatively lipophilic (logD 0.34) [26] and, therefore, a significant fraction of it will
likely interact with lipid bilayers, whereas at lower pH lipophilicity is reduced due to the appearance
of fully protonated forms (at pH 3.5, 99.6% of pyronaridine molecules are protonated in all three amino
groups [39]). When LPs are generated holding a pH gradient from 7.4 outside to 3.5 inside the vesicle
(Figure 2B), uncharged pyronaridine molecules present in the LP suspension will be able to enter the
liposomal lipid bilayer; there, those molecules eventually facing the luminal part of the vesicles will
be exposed to the intraliposomal acidic pH and protonated, leaving the membrane and becoming
encapsulated (Figure 2C,D). The encapsulation efficiency of pyronaridine incubated for 17 h with
such a pH gradient-sustaining LP suspension containing 5 mM lipid was >95% up to 0.5 mM drug
(Figure 2E), corresponding to a lipid:pyronaridine molar ratio close to 10:1. At higher pyronaridine
concentrations (1, 1.5, and 2 mM) the encapsulated fraction was proportionally lower (ca. 80%, 70%,
and 35%, respectively). The requirement for a correctly-oriented pH gradient is evidenced in controls
where the absence of a gradient or its inversion resulted in the lack of pyronaridine encapsulation
(Figure S4).
As pyronaridine becomes entrapped inside LPs, the internal proton pool is progressively depleted,
until eventually cancelling the pH gradient. To investigate if this pH gradient exhaustion led to drug
leakage, the amount of encapsulated pyronaridine in the samples from Figure 2E was followed over a
storage time of two weeks at 4 ◦C. At the starting concentrations of 0.5 and 1 mM drug, the percentage
of encapsulation was maintained relatively stable at about 90% and 80%, respectively, for the duration
of the assay (Figure 2F). At 2 mM pyronaridine the encapsulated drug was observed to increase during
the first week from ca. 35% to ca. 45%, indicating that after 17 h of incubation the LPs had not reached
their full encapsulation capacity. Since no drug leakage was observed over two weeks, we conclude
that pyronaridine uptake does not destabilize the LPs and that the pH gradient is preserved at least up
to the lipid:pyronaridine ratio of 10:4 (5 mM:2 mM).
Those LPs exhibiting the highest encapsulation efficiency (ca. 10:1 lipid:pyronaridine ratio) were
selected for a drug release assay (Figure 2G). After removing the non-encapsulated drug, the samples
were incubated in culture medium (either in the absence or in the presence of RBCs and pRBCs)
at 37 ◦C for 24 h, after which time only minor drug release was observed (≤6.5 ± 1.2%). Similar
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assays performed in storage conditions (incubation in PBS at 4 ◦C) resulted in even lower drug release
(ca. 1% after 24 h), presumably due to the reduced fluidity and, therefore, higher impermeability
of the LP lipid bilayer at this low temperature [40]. Control LPs treated with 2% SDS exhibited an
immediate drug release of around 90%, in agreement with the lipid bilayer solubilization induced by
the detergent [41]. Finally, somewhat surprisingly, LPs subjected to sonication released only about 35%
of encapsulated pyronaridine.
Figure 2. Pyronaridine encapsulation. (A) Pyronaridine structure with the pKas of relevant protonable
groups indicated. (B) Scheme of the transmembrane 7.4→3.5 pH gradient. (C,D) Scheme of pyronaridine
(Pyr) encapsulation. (E) Pyronaridine encapsulation efficiency (EE) in LPs (5 mM lipid) at different
initial drug concentrations. (F) Stability of pyronaridine encapsulation at 4 ◦C. (G) Pyronaridine release
assay from LPs (molar ratio lipid:pyronaridine ca. 10:1) incubated under different conditions (see text
for details).
3.2. Immunoliposome Targeting
Pyronaridine-loaded LPs (ca. 10:1 lipid:drug ratio) targeted with antibodies against the erythrocyte
membrane protein glycophorin A and labeled through the incorporation of 0.5% DOPE-Rho in
their formulation were prepared following established protocols [32]. Different dilutions of these
immunoliposomes were incubated with erythrocytes (3% hematocrit) and cell targeting was analyzed
by flow cytometry and fluorescence microscopy (Figure 3A). At a lipid concentration of 0.78 µM, >99%
RBC targeting by iLPs was achieved according to flow cytometry data, whereas only ~1% of cells were
associated with LPs not bearing antibody (Figure 3B). At 100 µM lipid ca. 21% of RBCs were targeted
by plain LPs; this result was not unexpected at such high liposome concentrations, and illustrates
the well-known capacity of liposomes to improve cargo delivery to cells. The stronger signal in
fluorescence microscopy images as the iLP concentration increased reflected the successive binding of a
higher number of iLPs on the cell surface. At 0.05 µM lipid about 33% of RBCs were still being targeted
by iLPs according to the threshold rhodamine signal defined by a LP-free erythrocyte control. To
confirm the strong binding of iLPs to target cells, RBCs (3% hematocrit) were incubated with different
rhodamine-labeled LP and iLP amounts and after 15 min of incubation the samples were spun down
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at a centrifuge force (300× g) sufficient to pellet RBCs but not LPs and iLPs. When the fluorescence of
the supernatants was determined it could be concluded that virtually all non-targeted LPs remained in
suspension whereas almost all iLPs were found in the cell pellet (Figure 3C). This result indicated that
iLP constituents remained bound to target cells in the presence of strong forces comparable or even
stronger than those encountered by RBCs in the blood circulation [42]. Gametocytes, which expose
glycophorin A on their membranes, were also targeted by iLPs (Figure 3D).
Figure 3. Immunoliposome targeting. (A,B) Flow cytometry and fluorescence microscopy RBC targeting
analysis of DOPE-Rho-labeled (A) anti-glycophorin A iLPs and (B) plain liposomes at different (i)LP
(expressed as lipid concentration):cell ratios. In each flow cytometry plot the fraction of targeted RBCs
is indicated. The fluorescence microscopy settings were adjusted for a correct exposure of the 100
µM lipid iLP sample. (C) Fluorescence analysis of the supernatants of centrifuged samples where
DOPE-Rho LPs and iLPs had been preincubated with RBCs. (D) Fluorescence microscopy targeting
analysis of the iLP sample to P. falciparum gametocytes. The arrowhead indicates a gametocyte.
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3.3. In Vitro Inhibition of P. falciparum Growth by iLPs Encapsulating Pyronaridine
In vitro growth inhibition assays of pyronaridine either in free form or encapsulated in LPs or
iLPs (Figure 4A,B, respectively), and left in the culture for the whole 48 h of incubation, did not reveal
significant differences among the three samples, which had a comparable IC50 around 19 nM (Figure 4C
and Table 1). In another set of assays, after 15 min of incubation, pyronaridine was removed and
replaced with fresh medium to better discern the effect of targeting and simulate drug removal in the
blood circulation. In this case the activity of the encapsulated drug was improved relative to that of
the free compound, a trend which was maintained when additional 15 min-spaced washing steps
were done (Figure 4C). Although the IC50 of samples treated with iLP-encapsulated pyronaridine
increased to ~74 nM after three washes (Table 1), the corresponding values for LP-encapsulated
pyronaridine and for the free drug augmented significantly more (to ~135 and ~146 nM, respectively).
The improvement in drug efficacy imparted by its encapsulation in iLPs was best observed for cultures
incubated at 100 nM pyronaridine, where all three samples exhibited 100% growth inhibition before
washing; after three washes; however, only the iLP-encapsulated drug maintained 100% activity at
this concentration, whereas free and LP-encapsulated pyronaridine had only 5% and 20% activity,
respectively. The reduced IC50 upon encapsulation in plain LPs vs. free drug is in agreement with the
observed interaction with RBCs of LPs lacking anti-GPA targeting (Figure 3B).
Figure 4. Pyronaridine growth inhibition assays in in vitro P. falciparum cultures. Scheme of
pyronaridine-encapsulating (A) LP and (B) iLP. (C) Growth inhibition assays where pyronaridine
was either (Unwashed) present for the whole 48 h of incubation or (Wash 1, 2, and 3) removed in
15 min-spaced washes.
Table 1. Pyronaridine IC50 values (nM) in in vitro P. falciparum cultures. 95% confidence intervals are
indicated in parentheses.
No Wash Wash 1 Wash 2 Wash 3
Free Pyr 20.6 (18.8–22.5) 57.2 (55.0–59.6) 113.6 (106.2–121.5) 146.4 (121.3–176.7)
LPs/Pyr 19.7 (17.7–21.9) 43.1 (40.0–46.3) 85.5 (80.7–90.7) 134.8 (128.1–141.9)
iLPs/Pyr 19.7 (18.5–21.0) 36.2 (17.4–75.2) 55.8 (52.4–59.4) 74.2 (62.0–88.8)
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3.4. Simultaneous Encapsulation in Liposomes of Pyronaridine and DB
The chemical structure of DB, with a long saturated carbon tail similar in dimensions to that
of phospholipids (Figure 5A,B), suggested that it could be incorporated into the lipid bilayer of LP
membranes without significantly altering their properties in terms of structure and the capacity to
encapsulate pyronaridine (Figure 5C). The incorporation of DB in liposomes was independent of the
presence of a pH gradient (Figure S5). DOPC-based liposomes, prepared incorporating increasing DB
amounts in their formulations, were loaded with pyronaridine at a lipid:pyronaridine molar ratio of ca.
10:1 using the pH gradient method described above. High pyronaridine encapsulation efficiencies
(>95%) were observed up to 2.5 mM DB (4:1 lipid:DB ratio; Figure 5D and Figure S6), but these dropped
to ca. 2% when reducing the lipid:DB ratio to 2:1 (Figure 5D). This result indicated that above a certain
DB content the liposome lipid bilayer becomes destabilized and is no longer capable of sustaining the
transmembrane pH drop required to encapsulate pyronaridine. CryoTEM examination confirmed that
at lipid:DB ratios down to 4:1, liposomes appeared well formed with an intact membrane (Figure 6B,C).
Although, at the lipid:DB ratio 2:1, liposomes formed correctly according to fluorescence microscopy
and dynamic light scattering analysis (Figure S2B,C), lipid bilayer alterations were evident in cryoTEM
images, such as oblong shapes and deteriorated membranes (Figure 6D–H).
Figure 5. Co-encapsulation in liposomes of pyronaridine and DB. (A,B) Chemical structures of
DOPC and DB. (C) Scheme of pyronaridine and DB co-encapsulation. (D) Encapsulation efficiency
(EE) of pyronaridine in liposomes (5 mM lipid, ca. 10:1 lipid:pyronaridine initial ratio) at different
lipid:DB ratios.
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Figure 6. CryoTEM analysis. (A) Scheme of the DB-encapsulating liposome. (B–H) Images of liposomes
containing different lipid:DB molar ratios. Arrowheads indicate deteriorated liposomes. Scale bars:
200 nm.
3.5. In Vitro Inhibition of P. falciparum Growth by iLPs Encapsulating DB
In vitro growth inhibition assays of DB, either in free form or encapsulated in LPs or iLPs, showed,
in washed samples, a significant improvement in the activity of iLP-encapsulated DB relative to
the free drug (Table 2). The IC50 of DB in in vitro P. falciparum cultures (~1 µM) was comparable to
that previously reported for fosmidomycin (0.29–0.37 µM [16]). However, as a consequence of the
limit in the maximum DB content that can be incorporated in liposomes without impairing their
stability, this relatively high IC50 required the addition to the cultures of DB-encapsulating iLPs in
quantities inducing erythrocyte agglutination (Figure S7). This result led us to discard DB for targeted
immunoliposome approaches. The antimalarial drug atovaquone, with an in vitro IC50 for P. falciparum
in the low nM range [35], comparable to that of pyronaridine, was selected for the proof-of-concept
assay of drug co-encapsulation in targeted iLPs. The dimensions and molecular shape of atovaquone,
similar to those of cholesterol (the lengths of both molecules are 14 and 15 C–C bonds, respectively),
suggested that it could comfortably fit into the lipid bilayer of a liposome.
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Table 2. DB IC50 values (µM) in in vitro P. falciparum cultures. 95% confidence intervals are indicated
in parentheses. Agglutinated (p)RBCs were discarded in flow cytometry parasitemia determinations.
No Wash Wash 1 Wash 2 Wash 3
Free DB 1.1 (1.0–1.3) 4.1 (3.6–4.8) 6.0 (5.3–6.8) 8.3 (7.0–9.7)
LPs/DB 1.7 (1.5–1.9) 12.0 (9.6–15.0) 28.9 (18.5–45.3) 34.9 (16.2–74.9)
iLPs/DB 1.0 (0.8–1.2) 2.0 (1.7–2.2) 2.4 (2.1–2.7) 3.0 (2.7–3.4)
3.6. In Vitro Inhibition of P. falciparum Growth by iLPs Co-Encapsulating Pyronaridine and Atovaquone
Atovaquone (Figure 7A) could be loaded in POPC-based liposomes (Figure 7B) with a maximum
encapsulation efficiency of about 50% (Figure 7C), although, because of its small IC50, this yield
permitted the incorporation of the drug amounts required to perform in vitro activity assays without
risk of inducing agglutination. As described above for pyronaridine and DB, the activity in
three-times-washed samples of atovaquone improved following its encapsulation in targeted liposomes,
with respective IC50 values for the free drug and iLP-drug of 77.6 and 18.6 nM (57.6–104.6 and 13.1–26.4
95% confidence intervals, respectively). Liposomes, prepared incorporating increasing atovaquone
amounts in their formulations, were loaded with pyronaridine at a lipid:pyronaridine molar ratio of 10:1
using the pH gradient method described above. High pyronaridine encapsulation efficiencies (>90%)
were observed up to a lipid:atovaquone ratio of 10:1 (Figure 7D), far above that required to obtain
in the in vitro P. falciparum cultures an inhibitory concentration of immunoliposomized atovaquone.
When immunoliposomes were prepared co-encapsulating pyronaridine and atovaquone (containing
10:0.5 lipid:atovaquone molar ratio; Figure 7E), their combined in vitro activity was significantly higher
than when both drugs were incorporated into the cultures in their free forms. At drug concentrations
that, in three-wash co-encapsulated immunoliposomized samples, induced a 50% of growth inhibition,
namely 43.1 nM atovaquone and 137.2 nM pyronaridine (29.6–62.7 and 90.7–207.4 95% confidence
intervals, respectively), the same amounts of free compounds did not reach 1% inhibition (Table 3).
The higher amount needed of each encapsulated individual drug to reach 50% growth inhibition, when
used in combination relative to when used alone, was also observed for the free compounds, which
required 116 nM atovaquone and 379 nM pyronaridine in three-times-washed samples.
Figure 7. iLPs co-encapsulating pyronaridine (Pyr) and atovaquone (Atv). (A) Atovaquone structure.
(B) Scheme of the atovaquone-encapsulating immunoliposome. (C) Atovaquone encapsulation efficiency
(EE) at different initial drug concentrations (10 mM lipid). (D) Encapsulation efficiency of pyronaridine in
liposomes (5 mM lipid, ca. 10:1 lipid:pyronaridine initial ratio) at different lipid:atovaquone molar ratios.
(E) Scheme of the immunoliposome encapsulating pyronaridine and atovaquone.
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Table 3. Percentages of growth inhibition in in vitro P. falciparum cultures at the corresponding drug
concentrations that induce a 50% inhibition in immunoliposomized samples.
% Inhibition at Drug IC50 of Immunoliposome Three-Wash Sample
Immunoliposomized Drug Liposomized Drug Free Drug
Pyronaridine 50.0 16.2 2.0
Domiphen bromide 50.0 0.2 3.5
Atovaquone 50.0 17.3 0.0
Atovaquone/pyronaridine 50.0 28.4 0.8
4. Discussion
It is generally accepted that to achieve malaria eradication a combination of weapons will be
needed [43], including the improvement of existing approaches and the development of new ones [44],
with drug therapy remaining the mainstay of treatment and prevention [45,46], and nanotechnology
being able to provide innovative useful tools [47]. When drugs are administered together in the
same nanostructure, they will be eliminated from the organism simultaneously with their carrier,
thus maintaining constant relative ratios throughout the treatment, which will likely end up in
improved pharmacokinetics. Co-nanoencapsulation of the antimalarials quinine and curcumin in
polysorbate-coated polymeric nanoparticles inhibited P. falciparum growth in vitro to a slightly larger
extent than identical amounts of the unencapsulated drugs [48]. In an in vivo study with the murine
malaria species Plasmodium berghei, curcumin-artesunate co-entrapped in poly(D,L-lactic-co-glycolic
acid) nanoparticles resulted in significant parasitemia reduction and increased mice survival when
compared with the free compounds [49].
Liposomes are particularly adept structures for nanosized combination delivery systems because
they allow the encapsulation of hydrophobic molecules in their lipid bilayer and of water-soluble
compounds in their lumen, thus being a potentially interesting platform for combination therapies
where lipophilic and hydrophilic drugs are delivered together in the same nanocarrier. The in vitro
activity in P. falciparum cultures of pyronaridine and atovaquone co-encapsulated in immunoliposomes
was significantly increased relative to the same amounts of both drugs in their free form. Because in the
cultures there is no preferential elimination of the non-encapsulated compounds, this improvement in
activity must be a consequence of the specific targeting of iLPs to pRBCs imparted by anti-glycophorin
A antibodies. When DOPE-Rho-containing, GPA-targeted iLPs were loaded with the hydrophilic
fluorescent dye pyranine and added to RBCs, both fluorescent labels were found in the cells [32].
The observed pattern suggested that, upon interaction, cells and liposomes eventually merged and, in
this process, the liposomal lipid bilayer (and any lipophilic drug present therein) was incorporated
into the cell membrane system, whereas the hydrophilic luminal content of the liposomes entered the
cytosol. The growth inhibition assays performed in this work have been done in parasite cultures
synchronized at early ring stages and with the drugs present for only 45 min. The observed improved
activity of immunoliposomized drugs indicates their rapid cell binding and efficient internalization. A
second benefit of targeting glycophorin A, an antigen present on all RBCs, is that, in this way, drugs
can be efficiently delivered to early parasite ring stages, which do not expose Plasmodium-specific
antigens, and to gametocytes. The finding that atovaquone and pyronaridine used together are less
active against the malaria parasite than when used alone suggests that this particular drug combination
is antagonistic. It is well known that, in combination therapies, susceptibility to one drug may alter
effectiveness of the other, leading to increased tolerance to both compounds [50].
Whereas current chemotherapeutic approaches against malaria are targeted at the asexual
blood stages that are responsible for all symptoms and pathologies of the disease [51], the threat
of resistance-driven treatment failure is prompting research oriented toward developing drugs that
target the weakest spots in the Plasmodium life cycle represented by smaller populations, which
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are less likely to contain resistant individuals that would benefit from the removal of susceptible
parasites [52]. The World Health Organization recommends, particularly in areas threatened by
resistance of P. falciparum to artemisinin [7], the implementation of strategies to reduce transmission of
the parasite forms that move between hosts [53,54]. Targeting gametocytes, the stage solely responsible
for the transmission from the human to the mosquito vector, can ease exposure of the pathogen to
drugs and reduce the likelihood of resistance emerging [54].
Isoprenoid precursor biosynthesis may be the only required essential function of the apicoplast
during Plasmodium blood stage development [55,56], which highlights the potential importance of
MEP pathway inhibitors for future malaria therapeutics. In enzymatic assays, DB had an IC50
~169 nM for P. vivax IspD [24], significantly lower than the value reported here for P. falciparum living
parasites (~1 µM). In in vitro activity assays done with the P. falciparum enzyme, the IspD inhibitor
MMV008138 had an IC50 of ~44 nM, which increased to ~350 nM against asexual stages in in vitro
cultures of the P. falciparum Dd2 strain [22,57], comparable to that of DB on the 3D7 strain used here.
The fosmidomycin IC50 for DXR is one order of magnitude higher in P. falciparum cultures (~370 nM
for the A2 strain) relative to the recombinant enzyme [16]. The results obtained here with DB indicate
that erythrocyte agglutination might be induced by immunoliposomes encapsulating drugs with an
IC50 for living parasites close to the µM range, which is the case for all MEP pathway inhibitors where
data are available.
The inactivity of fosmidomycin in in vitro cultures of the apicoplastidic protist Toxoplasma
gondii [57], which has DXR, is most likely due to the drug not reaching the enzyme location inside the
living parasite. Because the molecular targets of MEP pathway inhibitors are inside the apicoplast,
in order to exert their activity these drugs have to cross several lipid bilayers, namely those of the
RBC, the parasitophorous vacuole, the intraerythrocytic Plasmodium parasite itself, and the apicoplast.
As a result, the drug concentrations required to obtain antiparasitic activity increase significantly.
The liposomal prototype presented here is designed to shuttle drugs only through the first one of these
barriers. Future nanocarriers engineered to drive their contents also through some of the three other
biological membranes should be able to further reduce the IC50 of MEP pathway inhibitors to make
them a viable alternative for future clinically useful antimalarials.
The history of antimalarial chemotherapy clearly shows that resistance of the pathogen to every
new chemical developed against it has, without exception, evolved after a few years following its
deployment [58]. It will be; therefore, of the utmost importance to have efficient drug targeting strategies
in place for the moment when new drugs appear, in order to administer them to intraerythrocytic
malaria stages at sufficiently high local doses as to significantly reduce the evolution of resistant
parasites. The straightforward consequence will be that the few antimalarials hitting the market will
have a much more extended life before resistances evolve, which can give us an edge in the fight against
Plasmodium. The nanocarrier developed here for a targeted combination therapy at the nanoscale can
find an immediate application for the severe malaria cases that usually end up in health centers, where
the intravenous administration of liposomal formulations is feasible. Future challenges that have to be
dealt with include modifications of the nanocarrier in order to make it adequate for oral administration
formulations used in non-complicated malaria, which will likely involve polymer-based nanocapsules
instead of liposomes. A targeted nanomedicine like the one described above could be an essential tool
for a future eradication scenario where the last few cases of hyper-resistant Plasmodium strains will
have to be wiped off with extremely high local doses of combinations of future new drugs.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/7/341/s1,
Figure S1: Schematic representation of the preparation of the different liposomes used in this work, Figure S2:
Characterization of DSPC- and DOPC-based liposomes encapsulating DB, Figure S3: Scheme of the chemical
coupling of the anti-GPA antibody to a maleimide group-containing lipid, Figure S4: Pyronaridine encapsulation
in DOPC-based liposomes in the presence of a pH gradient, Figure S5: DB incorporation in DOPC-based liposomes
in the presence of a pH gradient, Figure S6: Pyronaridine encapsulation through the pH gradient method in
DOPC-based liposomes containing in their membranes DB at a total lipid:DB ratio 4:1, Figure S7: Flow cytometry
analysis of red blood cell agglutination induced by a suspension of immunoliposomes functionalized with
anti-GPA antibodies and containing 25 µM DB.
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